How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

851 results for

Antithyroid Drug

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Pattern of presentation of Graves’ disease and response to radioiodine therapy in South African men (PubMed)

at a university teaching hospital, in the Western Cape of South Africa.The overall cure rate was 76.4% for these male patients. Cure was observed as euthyroidism in 31 patients (15.3%) and hypothyroidism in 129 (63.5%). Age, thyroid uptake, severity of hyperthyroidism, previous antithyroid drug (ATD) usage, administered quantity of RAI, ethnicity and patients' pulse at presentation were not significant in influencing outcome.Factors which have been evaluated as affecting outcome of RAIT were unimportant

Full Text available with Trip Pro

2018 The Pan African medical journal

162. Plasma 3,3’,5-Triiodo-L-thyronine [T3] level mirrors changes in tumor markers in two cases of metastatic cancer of the breast and pancreas treated with exogenous L-T3 (PubMed)

and neoangiogenesis, therefore lowering endogenous T4 reduces tumor growth rate. We present the case of two patients with metastatic triple negative breast cancer and metastatic pancreatic cancer respectively, who benefit of the sole treatment with antithyroid drugs and exogenous administration of T3 (liothyronine). In these cases tumor growth was accompanied by T3 depletion in plasma, which may represent a novel marker for progression.

Full Text available with Trip Pro

2018 Cancer Biomarkers

163. A retrospective cohort study: do patients with graves’ disease need to be euthyroid prior to surgery? (PubMed)

A retrospective cohort study: do patients with graves’ disease need to be euthyroid prior to surgery? The 2016 American Thyroid Association guidelines indicate that patients with Graves' disease who undergo a thyroidectomy should be rendered euthyroid through the use of antithyroid drugs (ATD) prior to surgery to avoid complications such as a thyroid storm. At times, the use of ATDs can have limited efficacy and therefore some patients will inevitably remain biochemically hyperthyroid

Full Text available with Trip Pro

2018 Journal of Otolaryngology - Head & Neck Surgery

164. Prolactin-Producing Pituitary Carcinoma, Hypopituitarism, and Graves’ Disease—Report of a Challenging Case and Literature Review (PubMed)

with persistent symptoms. She developed growth hormone deficiency, central hypothyroidism, hypogonadism, and permanent diabetes insipidus. Six years later she was admitted for the suspicion of secondary adrenal insufficiency and thyrotoxicosis. Physical findings, laboratory data, thyroid ultrasound, and scintigraphy achieved the diagnosis of Graves' disease and hypocortisolism. She was treated with hydrocortisone and methimazole, but central hypothyroidism recurred after antithyroid drug withdrawal. Nine

Full Text available with Trip Pro

2018 Frontiers in endocrinology

165. Value of Apoptotic, Antiapoptotic, and Cell Proliferation Markers in the Treatment of Graves' Disease (PubMed)

level of MCL-1 in thyroid cells suggests that the hyperthyroid state was related to a lower antiapoptotic effect on thyrocytes. In comparison to patients with GD not using antithyroid drugs (ATD), we found a lower expression level of BID in lymphocytes for those who used ATD. Conclusion. In GD, the hyperthyroid state was associated with a lower antiapoptotic effect on thyroid cells. RIT, beta-blockers, and thionamide act by stimulating apoptosis of thyrocytes by intrathyroidal lymphocytes.

Full Text available with Trip Pro

2018 International journal of endocrinology

166. Graves Disease Causing Pancytopenia: Case Report and Literature Review (PubMed)

of mature hematopoietic cells. Despite unclear mechanism, the presence of hematologic abnormalities including pancytopenia must not be considered as a contraindication to antithyroid drug therapy.

Full Text available with Trip Pro

2018 Clinical medicine insights. Case reports

167. Prevalence and Annual Incidence of Thyroid Disease in Korea from 2006 to 2015: A Nationwide Population-Based Cohort Study (PubMed)

of incident cases of these three thyroid diseases steadily increased from 2006 to 2012, and then decreased through 2015. The incidence of thyroid nodules, hypothyroidism treated with thyroid hormone, and treated hyperthyroidism was 6.79/1,000 population, 1.76/1,000 population, and 0.55/1,000 population, respectively, in Korea in 2015. The use of methimazole continuously increased, from 33% of total antithyroid drug prescriptions in 2006 to 74.4% in 2015, and it became the most frequently prescribed (...) antithyroid drug in Korea. In contrast, the use of propylthiouracil continuously decreased.This was the first nationwide study of the prevalence and annual incidence of thyroid nodules, hypothyroidism, and hyperthyroidism to take into account recent changes and to include the current status of patients receiving treatment.Copyright © 2018 Korean Endocrine Society.

Full Text available with Trip Pro

2018 Endocrinology and Metabolism

168. Difficultés de prise en charge de la maladie de Basedow chez l’enfant: à propos d’un cas (PubMed)

is the first cause of hyperthyroidism in children. Positive diagnosis is easy but its management may pose enormous problems. Medical treatment is based on synthetic antithyroid drugs, but they are not always innocuous, as in the case of our patient. Then subtotal thyroidectomy or radioactive iodine treatment are two therapeutic alternatives. Graves' disease is a rare and severe disease in children posing considerable management difficulties.

Full Text available with Trip Pro

2018 The Pan African medical journal

169. Hypothyroidism With Congenital Heart Disease (CHD)

nervous system dysfunction. Maternal history of thyroid disease or antithyroid management. Methods : The study will be conducted in the Cardiology or Neonatology Units , Children's University Hospital, Faculty of Medicine, Assiut University on 50 patients both males and females. All children will be evaluated by thoroughly history taken. Full general (including the anthropometric measures) and cardiac examinations will be done. The patients will be conducted to investigations as: Thyroid function (...) Criteria: Patients with congenital heart diseases from birth (full term) to 3 years Exclusion Criteria: Patients with cardiac disease other than congenital heart disease Preterm infants Patients with other non cardiac congenital anomalies Other endocrinal or CNS dysfunction Maternal history of thyroid disease or antithyroid management Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff

2018 Clinical Trials

170. The Impact of the Hypnosis on the Loss of Weight at Patients in Failure of Bariatric Surgery

to understand the nature and the purpose of the study and\or communication difficulties with the investigator Patient having already benefited from a coverage by hypnotherapy for loss of weight Taken by treatment having an impact on the loss of weight (corticoid, antithyroid …) Major protected by the law Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided (...) -regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Keywords provided by University Hospital, Montpellier: Obesity bariatric surgery Hypnosis Additional relevant MeSH terms: Layout table for MeSH terms Weight Loss Body Weight Changes Body Weight Signs and Symptoms

2018 Clinical Trials

171. Liver Function After Intravenous Methylprednisolone Administration

treatment was performed during the study protocol. Condition or disease Intervention/treatment Phase Graves Disease Graves Ophthalmopathy Liver Diseases Liver Failure Liver Injury Liver Dysfunction Liver Insufficiency Acute Liver Failure Acute Liver Injury Acute Liver Injury, Drug Induced Methylprednisolone Adverse Reaction Glucocorticoids Toxicity Dysthyroid Orbitopathy Dysthyroid Ophthalmopathy Drug: every week IVMP therapy Drug: very high doses IVMP therapy Phase 4 Detailed Description: Depending (...) ), anti-smooth muscle antibodies (ASMA), anti-mitochondrial antibodies (AMA) and anti-liver kidney-microsomal antibodies (anti-LKM) were also assessed. Thyroid evaluation included measurement of: thyroid-stimulating hormone (TSH), free triiodothyronine (fT3), free thyroxine (fT4), and serum antithyroid autoantibodies including anti-thyroid peroxidase (aTPO), thyroglobulin antibodies (aTG), thyroid-binding inhibitory immunoglobulin (TBII). According to EUGOGO recommendations: patients with moderate

2018 Clinical Trials

172. A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis

(AI/Pen) Condition or disease Intervention/treatment Phase Post-Menopausal Osteoporosis Drug: HCP administration with PFS Device: Subject self-administration with AI/Pen Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 260 participants Allocation: Randomized Intervention Model: Parallel Assignment Intervention Model Description: After signing the informed consent form (ICF), subjects will undergo the following periods (...) romosozumab SC QM either by HCP administration with 2 PFS Drug: HCP administration with PFS subjects will receive 210 mg romosozumab SC QM either by HCP administration with 2 PFS Active Comparator: Subject self-administration with AI/Pen During the open-label treatment period, subjects will receive 210 mg romosozumab SC QM either by self-administration with 2 AI/Pens. Device: Subject self-administration with AI/Pen subjects will receive 210 mg romosozumab SC QM either by self-administration with 2 AI/Pens

2018 Clinical Trials

173. Propylthiouracil-coated biodegradable polymer inhibited neointimal formation and enhanced re-endothelialization after vascular injury (PubMed)

Propylthiouracil-coated biodegradable polymer inhibited neointimal formation and enhanced re-endothelialization after vascular injury The drug-eluting stent is a standard approach for the treatment of coronary artery disease. Propylthiouracil (PTU), an antithyroid drug, has been proven to suppress neointimal formation after balloon injury.This study used a biodegradable polymer coating with PTU to test its effects on platelet function, re-endothelialization, and neointimal formation after

Full Text available with Trip Pro

2018 International journal of nanomedicine

174. New insights into morphological, stereological and functional studies of the adrenal gland under exposure to the potent goitrogen thiourea (PubMed)

New insights into morphological, stereological and functional studies of the adrenal gland under exposure to the potent goitrogen thiourea Thiourea (thiophen-3-yl-acetic acid) is a well established antithyroid drug used for treating hyperactivity of the thyroid gland as it blocks the conversion of thyroxine (T4) to triiodothyronine (T3) in peripheral tissues. Human exposures to thiourea include contaminated drinking water and vegetables for its extensive use in fertilizers. Chronic thiourea (...) to that of the control. Increased lipid peroxidation (p=0.0054) and up-regulated corticosterone release (p=0.0064) through adrenocortical stress signalling pathway were also noted. Stereological analysis of the left adrenal gland showed significant increase in volume (p=0.0025) and mass of cells (p=0.0031) in adrenocortical region in comparison to that of control animals. This study concludes that thiourea, in addition to its antithyroidal activity, develops stress in the adrenal as evident by enhanced lipid

Full Text available with Trip Pro

2018 Interdisciplinary toxicology

175. Early Clinical Indicators of Addison's Disease in Adults with Type 1 Diabetes: a Nationwide, Observational, Cohort Study. (PubMed)

a higher frequency of thyroid/antithyroid drug prescription than controls (9.1% vs 1.8%). Prior to AD diagnosis, cases had higher frequencies of diabetic retinopathy (12.1% vs 2.1%), infections requiring hospital admission (16.7% vs 2.1%), thyroid/antithyroid drug prescription (28.8% vs 7.0%), and glucagon prescription (18.2% vs 6.4%). There was no difference in glycated Hb between the groups prior to baseline or prior to AD diagnosis.These data suggest that medical treatment of thyroid disease (...) Register (NDR), Inpatient Register, and Prescription Drug Register].All patients with T1DM diagnosed with concomitant AD (n = 66) among the 36,514 adult patients with T1DM in the NDR between 1998 and 2013. Each case was matched to five controls with T1DM alone (n = 330).Clinical data and drug prescriptions were assessed prior to baseline (inclusion into the study) and prior to AD diagnosis. Analysis of covariance and estimated group proportions were used for comparisons.Prior to baseline, cases had

2018 Journal of Clinical Endocrinology and Metabolism

176. Resistant Thyrotoxicosis due to Graves' Disease in Pregnancy: Case Report and Review of the Literature (PubMed)

Resistant Thyrotoxicosis due to Graves' Disease in Pregnancy: Case Report and Review of the Literature The effective management of Graves' disease (GD) during pregnancy is crucial for maternal and neonatal well-being. Conventional treatment of GD during pregnancy includes antithyroid drugs (ATDs) and surgery, ideally during the second trimester. We report a 27-year-old woman with GD and we present the course of GD during her three consecutive pregnancies. During the first pregnancy (...) , thyrotoxicosis was successfully treated with low doses of antithyroid drugs; in the second pregnancy, thyrotoxicosis was only controlled at the third trimester; while in the third pregnancy, our patient presented with treatment-resistant thyrotoxicosis, which was finally managed with corticosteroids in adjunction with ATDs. Although hyperthyroid, the patient maintained her fertility. Resistance to ATD is a rare condition and in our case was adequately controlled with corticosteroids.

Full Text available with Trip Pro

2018 Cureus

177. Determination of Baseline Thyroid Status Values in French Adult Population

Accepts Healthy Volunteers: Yes Criteria Inclusion Criteria: Donors (18-70 years old) volunteers at EFS Exclusion Criteria: pregnancy, known antecedents of thyroid diseases (goiter, nodule, hypo or hyperthyroidism), current antithyroid treatment (neomercazole [Thyrozol(r)], levothyroxyn LT4 [levothyrox(r)], ...), cardiac treatment with amiodarone (cordarone(r)), injection of iodinated contrast medium less than 1 month old Contacts and Locations Go to No Contacts or Locations Provided More Information (...) Go to Layout table for additonal information Responsible Party: University Hospital, Caen ClinicalTrials.gov Identifier: Other Study ID Numbers: 18-040 First Posted: November 20, 2018 Last Update Posted: November 20, 2018 Last Verified: November 2018 Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No

2018 Clinical Trials

178. Clinical Feasibility of Continuously Monitored Data for Heart Rate, Physical Activity, and Sleeping by Wearable Activity Trackers in Patients with Thyrotoxicosis: Protocol for a Prospective Longitudinal Observational Study (PubMed)

Clinical Feasibility of Continuously Monitored Data for Heart Rate, Physical Activity, and Sleeping by Wearable Activity Trackers in Patients with Thyrotoxicosis: Protocol for a Prospective Longitudinal Observational Study Thyrotoxicosis is a common disease caused by an excess of thyroid hormones. The prevalence of thyrotoxicosis about 2% and 70-90% of thyrotoxicosis cases are caused by Graves' disease, an autoimmune disease, which has a high recurrence rate when treated with antithyroid drugs

Full Text available with Trip Pro

2018 JMIR Research Protocols

179. Elevated Serum IL-17 Expression at Cessation Associated with Graves' Disease Relapse (PubMed)

Elevated Serum IL-17 Expression at Cessation Associated with Graves' Disease Relapse Antithyroid drug (ATD) treatment occupies the cornerstone therapeutic modality of Graves' disease (GD) with a high relapse rate after discontinuation. This study aimed to assess potential risk factors for GD relapse especially serum interleukin-17 (IL-17) expression.Consecutive newly diagnosed GD patients who were scheduled to undergo ATD therapy from May 2011 to May 2014 were prospectively enrolled. Risk

Full Text available with Trip Pro

2018 International journal of endocrinology

180. Incidence of neonatal hyperthyroidism among newborns of Graves' disease patients treated with radioiodine therapy. (PubMed)

of NH among newborns of mothers who conceived within two years after RAI therapy, and to identify predictors of NH.GD patients (n = 145) who conceived within two years after RAI therapy were retrospectively reviewed, and information regarding their newborns was collected.Of the 145 pregnant women, 54 (37%) were treated with antithyroid drugs or potassium iodide for maternal hyperthyroidism during the first trimester. There were eight newborns with NH, resulting in an incidence of 5.5%. Seven (...) of the eight mothers whose newborns had NH were treated with antithyroid drugs or potassium iodide during their pregnancy. The incidence of NH among the newborns of mothers who conceived within 6-12 months after RAI therapy was 8.8%, within 12-18 months was 5.5%, and within 18-24 months was 3.6%. Multivariate analysis revealed that the TRAb values in the third trimester were the only risk factor for NH. The cutoff TRAb value in the third trimester for predicting NH was 9.7 IU/L (reference value <2.0 IU/L

2018 Thyroid

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>